Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT: NCT03647358 · RECRUITING

NCT IDNCT03647358
StatusRECRUITING
Start Date2018-08-21
Completion2027-08

Brief Summary

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Frequently Asked Questions

What is Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma?

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma is a clinical trial registered under NCT03647358. Current status: RECRUITING.

What is the status of NCT03647358?

The current status of NCT03647358 (Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma) is: RECRUITING.

When did Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma start?

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma started on 2018-08-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.